Following an outcry over safety concerns, CVS will return Bristol Myers Squibb and Pfizer’s Eliquis to its national preferred formulary July 1, according to reporting from Modern Healthcare. The blood thinner was removed in January, with patients advised to switch to Johnson & Johnson’s Xarelto. This sparked pushback from providers, however, as abruptly switching blood thinners can pose health risks to patients. 90% of all insured lives currently have preferred access to Eliquis under the pharmacy benefit, to Xarelto’s 99%.
SOURCE: MMIT Analytics, as of 6/27/22